Related references
Note: Only part of the references are listed.Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives
E. Martinelli et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study
Kai-Keen Shiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?
Giulia Martini et al.
CANCER TREATMENT REVIEWS (2020)
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment inKRASwild-type metastatic colorectal cancer: JACCRO CC-08
Toshiki Masuishi et al.
BRITISH JOURNAL OF CANCER (2020)
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer
Morena Fasano et al.
ESMO OPEN (2020)
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies
Gianluca Mauri et al.
CANCER TREATMENT REVIEWS (2019)
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Davide Ciardiello et al.
CANCER TREATMENT REVIEWS (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer (vol 30, pg 157, 2019)
G. Siravegna et al.
ANNALS OF ONCOLOGY (2019)
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
C. M. Parseghian et al.
ANNALS OF ONCOLOGY (2019)
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience
Pietro Paolo Vitiello et al.
CANCERS (2019)
Product review: avelumab, an anti-PD-L1 antibody
Julie M. Collins et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer A Randomized Phase 2 Clinical Trial
Chiara Cremolini et al.
JAMA ONCOLOGY (2018)
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).
Alexander Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer
Yuka Inoue et al.
CANCER SCIENCE (2017)
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D. Santini et al.
ANNALS OF ONCOLOGY (2012)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
